What are the treatment regimens for diffuse large B-cell lymphoma (DLBCL) with concurrent CNS disease?

Updated: Feb 23, 2021
  • Author: Mohammad Muhsin Chisti, MD, FACP; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

Regimens for concurrent presentation with CNS disease are as follows:

  • Parenchymal: 3 g/m 2 or more of systemic methotrexate given on day 15 of a 21-day R-CHOP cycle with growth factor support
  • Leptomeningeal: Intrathecal methotrexate/cytarabine; consider Ommaya reservoir placement and/or systemic methotrexate (3–3.5 g/m 2)

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!